GoodRx Stock Forecast, Price & News

+2.16 (+4.88 %)
(As of 09/16/2021 03:16 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume40,855 shs
Average Volume1.99 million shs
Market Capitalization$18.38 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GDRX News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GoodRx logo

About GoodRx

GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.12 out of 5 stars

Medical Sector

434th out of 1,352 stocks

Data Processing & Preparation Industry

28th out of 93 stocks

Analyst Opinion: 2.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

GoodRx (NASDAQ:GDRX) Frequently Asked Questions

Is GoodRx a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GoodRx stock.
View analyst ratings for GoodRx
or view top-rated stocks.

What stocks does MarketBeat like better than GoodRx?

Wall Street analysts have given GoodRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GoodRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GoodRx?

GoodRx saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 19,100,000 shares, an increase of 18.5% from the July 29th total of 16,120,000 shares. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is currently 10.7 days. Currently, 30.9% of the shares of the company are sold short.
View GoodRx's Short Interest

When is GoodRx's next earnings date?

GoodRx is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for GoodRx

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings results on Thursday, August, 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.07. The business earned $176.64 million during the quarter, compared to analysts' expectations of $174.15 million. GoodRx had a negative trailing twelve-month return on equity of 39.62% and a negative net margin of 50.01%.
View GoodRx's earnings history

What guidance has GoodRx issued on next quarter's earnings?

GoodRx updated its third quarter 2021 earnings guidance on Thursday, September, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $193 million-$197 million, compared to the consensus revenue estimate of $195.15 million.

What price target have analysts set for GDRX?

15 Wall Street analysts have issued twelve-month target prices for GoodRx's stock. Their forecasts range from $29.00 to $70.00. On average, they expect GoodRx's stock price to reach $47.93 in the next year. This suggests a possible upside of 3.2% from the stock's current price.
View analysts' price targets for GoodRx
or view top-rated stocks among Wall Street analysts.

Who are GoodRx's key executives?

GoodRx's management team includes the following people:

Who are some of GoodRx's key competitors?

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

(GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

What is GoodRx's stock symbol?

GoodRx trades on the NASDAQ under the ticker symbol "GDRX."

Who are GoodRx's major shareholders?

GoodRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.32%), Morgan Stanley (1.03%), Morgan Stanley (1.03%), Atreides Management LP (0.87%), FMR LLC (0.46%) and Carmignac Gestion (0.45%). Company insiders that own GoodRx stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann and Lake Group LLC Silver.
View institutional ownership trends for GoodRx

Which major investors are selling GoodRx stock?

GDRX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., FMR LLC, Citadel Advisors LLC, Zevenbergen Capital Investments LLC, Bienville Capital Management LLC, Putnam Investments LLC, and Light Street Capital Management LLC. Company insiders that have sold GoodRx company stock in the last year include Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, and Karsten Voermann.
View insider buying and selling activity for GoodRx
or view top insider-selling stocks.

Which major investors are buying GoodRx stock?

GDRX stock was bought by a variety of institutional investors in the last quarter, including Atreides Management LP, Vanguard Group Inc., Carmignac Gestion, Jefferies Group LLC, Teacher Retirement System of Texas, Bridgewater Associates LP, Nuveen Asset Management LLC, and Luxor Capital Group LP. Company insiders that have bought GoodRx stock in the last two years include Abdiel Capital Management, Llc, and Lake Group LLC Silver.
View insider buying and selling activity for GoodRx
or or view top insider-buying stocks.

How do I buy shares of GoodRx?

Shares of GDRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GoodRx's stock price today?

One share of GDRX stock can currently be purchased for approximately $46.45.

How much money does GoodRx make?

GoodRx has a market capitalization of $18.38 billion and generates $550.70 million in revenue each year. The company earns $-293,620,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

How many employees does GoodRx have?

GoodRx employs 462 workers across the globe.

What is GoodRx's official website?

The official website for GoodRx is

Where are GoodRx's headquarters?

GoodRx is headquartered at 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401.

How can I contact GoodRx?

GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company can be reached via phone at 855-268-2822 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.